Rohan Hazra

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection
    Rohan Hazra
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Pediatrics 116:e846-54. 2005
  2. doi request reprint Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection
    Rohan Hazra
    Pediatric, Adolescent and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Center for Research for Mothers and Children, National Institutes of Health, Rockville, Maryland 20852, USA
    Annu Rev Med 61:169-85. 2010
  3. pmc HIV Drug Resistance-Associated Mutations in Antiretroviral Naïve HIV-1-Infected Latin American Children
    Luis E Soto-Ramirez
    Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y Nutricion, 14000 Ciudad de México, DF, Mexico
    Adv Virol 2010:407476. 2010
  4. pmc Insulin resistance and glucose and lipid concentrations in a cohort of perinatally HIV-infected Latin American children
    Rohan Hazra
    Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892 7510, USA
    Pediatr Infect Dis J 32:757-9. 2013
  5. ncbi request reprint Immunologic, virologic, and neuropsychologic responses in human immunodeficiency virus-infected children receiving their first highly active antiretroviral therapy regimen
    Rohan Hazra
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1868, USA
    Viral Immunol 20:131-41. 2007
  6. doi request reprint Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children
    Rohan Hazra
    Pediatric, Adolescent, and Maternal AIDS Branch, CRMC NICHD NIH, Bethesda, MD 20892 7510, USA
    AIDS 26:235-40. 2012
  7. ncbi request reprint Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children
    Rachel I Gafni
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Pediatrics 118:e711-8. 2006
  8. pmc Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment
    Paige L Williams
    aCenter for Biostatistics in AIDS Research bDepartment of Biostatistics, Harvard School of Public Health, Boston, Massachusetts cDepartment of Pediatrics Infectious Diseases, University of Colorado School of Medicine and Children s Hospital Colorado, Aurora, Colorado dTulane University School of Medicine, New Orleans, Louisiana eEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland fDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts gSection of Pediatric Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana hDepartment of Pediatrics, University of Colorado School of Medicine, Denver, Colorado iNew York University School of Medicine, New York jDepartment of Pediatrics, New Jersey Medical School, Newark, New Jersey kSaban Research Institute, Children s Hospital Los Angeles, Los Angeles, California, USA
    AIDS 27:1959-70. 2013
  9. pmc Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children
    Sarah K Himes
    From the Chemistry and Drug Metabolism Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland Department of Epidemiology, Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland Department of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana and Pediatrics Department, University of Illinois at Chicago, Chicago, Illinois
    Pediatr Infect Dis J 34:851-7. 2015
  10. pmc Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus
    Julia B Purdy
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Pediatr 152:582-4. 2008

Detail Information

Publications36

  1. ncbi request reprint Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection
    Rohan Hazra
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Pediatrics 116:e846-54. 2005
    ..We designed this study to provide preliminary pediatric safety and dosing information on tenofovir DF, while also providing potentially efficacious salvage therapy for heavily treatment-experienced, HIV-infected children...
  2. doi request reprint Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection
    Rohan Hazra
    Pediatric, Adolescent and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Center for Research for Mothers and Children, National Institutes of Health, Rockville, Maryland 20852, USA
    Annu Rev Med 61:169-85. 2010
    ....
  3. pmc HIV Drug Resistance-Associated Mutations in Antiretroviral Naïve HIV-1-Infected Latin American Children
    Luis E Soto-Ramirez
    Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y Nutricion, 14000 Ciudad de México, DF, Mexico
    Adv Virol 2010:407476. 2010
    ..Mutations associated with resistance to nucleoside reverse transcriptase inhibitors were the most prevalent...
  4. pmc Insulin resistance and glucose and lipid concentrations in a cohort of perinatally HIV-infected Latin American children
    Rohan Hazra
    Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892 7510, USA
    Pediatr Infect Dis J 32:757-9. 2013
    ..Continued follow-up of this population is necessary to characterize the evolution and clinical consequences of these findings. ..
  5. ncbi request reprint Immunologic, virologic, and neuropsychologic responses in human immunodeficiency virus-infected children receiving their first highly active antiretroviral therapy regimen
    Rohan Hazra
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1868, USA
    Viral Immunol 20:131-41. 2007
    ....
  6. doi request reprint Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children
    Rohan Hazra
    Pediatric, Adolescent, and Maternal AIDS Branch, CRMC NICHD NIH, Bethesda, MD 20892 7510, USA
    AIDS 26:235-40. 2012
    ..Dyslipidemia is observed among older children and adults with HIV. We examined nonfasting cholesterol and triglycerides in two groups of 12-23-month-old Latin American children - HIV-infected vs. HIV-exposed but uninfected (HEU)...
  7. ncbi request reprint Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children
    Rachel I Gafni
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Pediatrics 118:e711-8. 2006
    ..We hypothesized that, given the higher rate of bone turnover that is associated with normal skeletal growth, the potential for TDF-related bone toxicity may be greater in children than in adults...
  8. pmc Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment
    Paige L Williams
    aCenter for Biostatistics in AIDS Research bDepartment of Biostatistics, Harvard School of Public Health, Boston, Massachusetts cDepartment of Pediatrics Infectious Diseases, University of Colorado School of Medicine and Children s Hospital Colorado, Aurora, Colorado dTulane University School of Medicine, New Orleans, Louisiana eEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland fDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts gSection of Pediatric Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana hDepartment of Pediatrics, University of Colorado School of Medicine, Denver, Colorado iNew York University School of Medicine, New York jDepartment of Pediatrics, New Jersey Medical School, Newark, New Jersey kSaban Research Institute, Children s Hospital Los Angeles, Los Angeles, California, USA
    AIDS 27:1959-70. 2013
    ..To evaluate associations of perinatal HIV infection, HIV disease severity, and combination antiretroviral treatment with age at pubertal onset...
  9. pmc Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children
    Sarah K Himes
    From the Chemistry and Drug Metabolism Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland Department of Epidemiology, Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland Department of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana and Pediatrics Department, University of Illinois at Chicago, Chicago, Illinois
    Pediatr Infect Dis J 34:851-7. 2015
    ..Fetal TFV toxicity was demonstrated in animals, but most clinical investigations have not observed toxicity in humans...
  10. pmc Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus
    Julia B Purdy
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Pediatr 152:582-4. 2008
    ..1 subject was the smallest child and experienced a 27% decrease, necessitating withdrawal of TDF. Subsequently, her BMD recovered. Monitoring of children infected with HIV who require treatment with TDF is warranted...
  11. pmc Combination antiretroviral use and preterm birth
    D Heather Watts
    Pediatric, Adolescent, and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute for Child Health and Human Development, Bethesda, Maryland, USA
    J Infect Dis 207:612-21. 2013
    ..Use of antiretroviral drugs (ARVs) during pregnancy has been associated with higher risk of preterm birth...
  12. ncbi request reprint Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens
    Perdita Taylor
    Pediatric HIV Working Group, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Pediatrics 114:e235-42. 2004
    ....
  13. pmc Dyslipidemia in a cohort of HIV-infected Latin American children receiving highly active antiretroviral therapy
    Margaret Brewinski
    Pediatric, Adolescent and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development NICHD, National Institutes of Health, Bethesda, MD 20892 7510, USA
    J Trop Pediatr 57:324-32. 2011
    ..In conclusion, HIV-infected youth receiving PI-containing HAART in this Latin American cohort were at increased risk for hypercholesterolemia and hypertriglyceridemia compared with those receiving NNRTI-containing HAART...
  14. pmc Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design
    Paige L Williams
    aCenter for Biostatistics in AIDS ResearchbDepartment of Biostatistics, Harvard T H Chan School of Public Health, Boston, MassachusettscEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MarylanddTulane University School of Medicine, New Orleans, LouisianaeUniversity of Alabama at Birmingham, Departments of Pediatrics and Microbiology, Birmingham, AlabamafDepartment of Epidemiology, Harvard T H Chan School of Public Health, Boston, MassachusettsgChildren s National Medical Center, Washington, DChFrontier Science Technology and Research Foundation FSTRF, Amherst, New YorkiUniversity of Illinois at Chicago, Chicago, Illinois, USA
    AIDS 30:133-44. 2016
    ..To evaluate the safety of in-utero antiretroviral exposure in children born to mothers with HIV, using a trigger-based design...
  15. pmc CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States
    Lee Fairlie
    aWits Reproductive Health and HIV Institute WRHI, University of the Witwatersrand, Johannesburg, South Africa bDepartment of Epidemiology, Center for Biostatistics in AIDS Research CBAR, Harvard School of Public Health, Boston, Massachusetts cTulane University School of Medicine, New Orleans, Louisiana dEunice Kennedy Shriver National Institute of Child Health and Human Development NICHD, National Institutes of Health, Bethesda, Maryland eHarvard MIT Division of Health Sciences and Technology, Boston, Massachusetts fJohns Hopkins University School of Medicine, Baltimore, Maryland gJacobi Medical Center Family Based Services, Albert Einstein College of Medicine, Bronx, New York, USA
    AIDS 29:2109-19. 2015
    ..This study compared 12-month CD4 and viral load outcomes in HIV-infected children and adolescents with virological failure, managed with four treatment switch strategies...
  16. pmc Evaluation of viral load thresholds for predicting new World Health Organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy
    George K Siberry
    Pediatric, Adolescent, and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892 7510, USA
    J Acquir Immune Defic Syndr 60:214-8. 2012
    ..This study evaluated a wide range of viral load (VL) thresholds to identify a cut-point that best predicts new clinical events in children on stable highly active antiretroviral therapy (HAART)...
  17. ncbi request reprint Emergence of human immunodeficiency virus type 1 variants containing the Q151M complex in children receiving long-term antiretroviral chemotherapy
    Shigeyoshi Harada
    Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Antiviral Res 75:159-66. 2007
    ..These data suggest that the Q151M could be prevalent in pediatric patients with long-term NRTI monotherapy and/or dual NRTI regimens and that HAART regimens containing TDF may be meritorious in such patients...
  18. pmc Virologic response using directly observed therapy in adolescents with HIV: an adherence tool
    Julia Bilodeau Purdy
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Assoc Nurses AIDS Care 19:158-65. 2008
    ..A period of clinic-monitored DOT may allow diagnosis of nonadherence, discussion of medication barriers, and avoidance of unnecessary medication changes...
  19. pmc Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents
    Paul Krogstad
    aDepartment of Pediatrics Infectious Diseases bDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California cDepartment of Epidemiology, Center for Biostatistics in AIDS Research CBAR, Harvard School of Public Health, Boston, Massachusetts dEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland eUniversity of Colorado School of Medicine and Children s Hospital Colorado, Aurora, Colorado fDepartment of Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey gNew York University School of Medicine hAlbert Einstein College of Medicine, New York City, New York, USA iDepartment of Pediatrics, Federal University of Minas Gerais, Minas Gerais, Brazil jTulane University School of Medicine, New Orleans, Louisiana, USA
    AIDS 29:683-93. 2015
    ..The frequency, severity and significance of these discordant treatment responses remain unclear...
  20. pmc Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood
    David Dimock
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
    Metabolism 60:874-80. 2011
    ..002). Impaired glucose tolerance, insulin resistance, dyslipidemia, and microalbuminuria are common among young adults with HIV. Long-term exposure to therapy may translate into substantial persistent metabolic risk...
  21. pmc Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants
    George K Siberry
    Pediatric Adolescent Maternal AIDS Branch, Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    AIDS 26:1151-9. 2012
    ..To evaluate the association of tenofovir disoproxil fumarate (TDF) use during pregnancy with early growth parameters in HIV-exposed, uninfected (HEU) infants...
  22. pmc CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption
    George K Siberry
    Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
    J Acquir Immune Defic Syndr 57:223-9. 2011
    ..To assess the characteristics and outcomes of antiretroviral treatment (ART) interruption (TI) in perinatally HIV-infected children...
  23. pmc Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy
    George K Siberry
    Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland
    Clin Infect Dis 61:996-1003. 2015
    ..Fetal bone effects of maternal tenofovir use have not been well studied. We sought to compare whole-body bone mineral content (BMC) of newborns exposed vs not exposed to tenofovir in utero...
  24. pmc Prevalence and predictors of elevated aspartate aminotransferase-to-platelet ratio index in Latin American perinatally HIV-infected children
    George K Siberry
    From the Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda Westat, Rockville, MD Department of Infectious Diseases, Hospital Federal dos Servidores do Estado Instituto de Puericultura e Pediatria Martagão Gesteira, Universidade Federal do Rio de Janeiro, Rio de Janeiro Vertical Transmission Unit, Femina Hospital, Porto Alegre Department of Pediatrics, University of São Paulo Faculty of Medicine of Ribeirão Preto, Ribeirão Preto and Department of Pediatrics, Federal University of Minas Gerais, Belo Horizonte, Brazil
    Pediatr Infect Dis J 33:177-82. 2014
    ..We characterized elevated aspartate aminotransferase-to-platelet ratio index (APRI), a marker of possible liver fibrosis, in perinatally HIV-infected children...
  25. ncbi request reprint Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART)
    Staci C Martin
    HIV and AIDS Malignancy Branch, National Cancer Institute, 9030 Old Georgetown Road, Bethesda, MD 20814, USA
    Dev Neuropsychol 30:633-57. 2006
    ..Findings emphasize the importance of conducting neuropsychological assessments in this population, particularly for children with cortical atrophy and absolute CD4+ cell counts < or = 500...
  26. doi request reprint Family functioning and coping styles in families of children with cancer and HIV disease
    Staci Martin
    National Cancer Institute, Bethesda, MD, USA
    Clin Pediatr (Phila) 51:58-64. 2012
    ..Researchers should avoid combining various illness groups indiscriminately. Likewise, clinicians should be sensitive to disease-specific factors when helping families learn to cope with illness-related stressors...
  27. ncbi request reprint Thymic function in HIV infection
    Rohan Hazra
    Pediatric Oncology Branch, National Cancer Institute, Bldg 10 CRC Rm 1W 3940, 10 Center Drive, MSC 1104, Bethesda, MD 20892, USA
    Curr HIV/AIDS Rep 2:24-8. 2005
    ..Recent work has demonstrated that some HIV strains, especially those that are CXCR4 trophic, are more thymotoxic and may contribute to irreversible thymic damage in this population...
  28. pmc Planning Future Strategies for Domestic and International NeuroAIDS Research, July 24-25, 2008
    Jeymohan Joseph
    HIV Pathogenesis, Neuropsychiatry and Treatment Branch, Center for Mental Health Research on AIDS, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    J Neuroimmune Pharmacol 4:283-97. 2009
    ..Several critical research areas in neuroAIDS were identified as areas of emphasis. Opportunities for collaborations between large NIH-funded projects were also discussed...
  29. pmc Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, t
    Lynne M Mofenson
    National Institutes of Health, Bethesda, Maryland, USA
    MMWR Recomm Rep 58:1-166. 2009
    ..nih.gov...
  30. pmc High rate of coronary artery abnormalities in adolescents and young adults infected with human immunodeficiency virus early in life
    Irene J Mikhail
    National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892 1662, USA
    Pediatr Infect Dis J 30:710-2. 2011
    ..More than 50% of participants (14/27) had evidence of CAA. Individuals had a high rate of CAA, suggesting possible early atherosclerosis...
  31. pmc Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure
    Sarah K Himes
    Chemistry and Drug Metabolism Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD Speech, Language, Hearing Department, University of Kansas, Lawrence, KS Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA and Department of Research Pediatrics, Maternal, Child, and Adolescent Program for Infectious Diseases and Virology, Keck School of Medicine of USC, Los Angeles, CA
    J Acquir Immune Defic Syndr 69:178-86. 2015
    ..Prenatal ATV exposure previously was associated with poorer language development in 1-year olds...
  32. pmc Preexposure prophylaxis for adolescents and young adults at risk for HIV infection: is an ounce of prevention worth a pound of cure?
    Jill E Pace
    Pediatric, Adolescent and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892 7510, USA
    Clin Infect Dis 56:1149-55. 2013
    ..YMSM and minority youth are at substantial HIV risk and urgently need effective HIV prevention tools for which the short and long-term benefits and risks have been carefully considered...
  33. ncbi request reprint Evidence of human immunodeficiency virus type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue
    Lynnae Schwartz
    Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 1296, USA
    J Neurovirol 13:274-83. 2007
    ..HIV-1 or viral DNA was identified in nestin-positive cells in four of seven HIV-1-infected children, suggesting in vivo infection of neural progenitors...
  34. pmc Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093
    Rolando M Viani
    From the Department of Pediatrics, University of California, San Diego, California Rady Children s Hospital San Diego, La Jolla, California Statistical and Data Analysis Center, Harvard School Public Health, Boston, Massachusetts University of Alabama at Birmingham, Birmingham, Alabama Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland HJF DAIDS, A Division of the Henry Jackson Foundation, Contractor to the Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland GlaxoSmithKline, Research Triangle Park, North Carolina and Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York
    Pediatr Infect Dis J 34:1207-13. 2015
    ..To assess the pharmacokinetics (PK), safety and efficacy of dolutegravir plus optimized background regimen in HIV-infected treatment-experienced adolescents...
  35. pmc Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children
    Rohan Hazra
    HIV and AIDS Malignancy Branch, Biostatistics and Data Management Section, National Cancer Institute, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 48:124-9. 2004
    ..h/ml; C(max), approximately 300 ng/ml) treated with tenofovir DF at 300 mg...
  36. ncbi request reprint HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response
    Margaret E Feeney
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Immunol 174:7524-30. 2005
    ..Taken together, these findings indicate that the developing immune system of children may exhibit greater plasticity in responding to a continually evolving chronic viral infection...